JS
Jack W Schuler (Director) filed 4 Form 4 reports in the trailing twelve months (4 purchases, 0 sales), most often in Biodesix, Inc. (BDSX). Across 4 priced purchase filings, the average 21-session return was +13.9% from execution and +12.2% from disclosure (delay-adjusted; derived). The largest single filing was $1.2M of BDSX (100,000 sh across 2 lots, as filed), executed Jan 23. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+13.9%
avg across 4 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+12.2%
same 4 filings, from disclosure
Filings, ttm
4
4 buys · 0 sells
Median delay
3d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$3.1M
shares × price, as filed
Last traded
Aug 12
Filed Aug 13
Median ADV $1.8M across their filed names
Impact on $10,000 · 12M
$11,717 (+17.2%)
S&P 500 $10,907 (+9.1%) · 8.1 pts ahead
Jack W Schuler
S&P 500
Derived: compounded across filings from disclosure dates · past 12 months
Open performance→Volume by month
Buys $4.6M
Sells $314K
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
4 filings
Sector per market data · by filing · past 12 months
Most traded names
BDSXRecent filings
AXDXSALE
Accelerate Diagnostics, Inc
View filing →
$314K200,000 sh × $1.57
Exec Dec 3 2024
Filed Dec 3 2024 · 5:30 PM ET BDSXPURCHASE Biodesix, Inc. View filing → –
100,000 sh · price not plausible
Exec Nov 21 2024
Filed Nov 22 2024 · 5:30 PM ET BDSXPURCHASE Biodesix, Inc. View filing → –
200,000 sh · price not plausible
Exec Nov 20 2024
Filed Nov 21 2024 · 5:30 PM ET BDSXPURCHASE Biodesix, Inc. View filing → –
100,253 sh · price not plausible
Exec Nov 5 2024
Filed Nov 6 2024 · 5:30 PM ET